Using pulsed radiofrequency and platelet-rich plasma to treat glossopharyngeal neuralgia
Efficacy and Safety of the Application of Pulsed Radiofrequency, Combined With Platelet Rich Plasma, to the Treatment of Idiopathic Glossopharyngeal Neuralgia (GPN): A Study Protocol for a Multi-Center, Prospective, Open-Label, Propensity Score Match Cohort Study
This study is testing if combining pulsed radiofrequency treatment with platelet-rich plasma can help adults with glossopharyngeal neuralgia who haven't found relief from medications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 121 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06931457 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness and safety of combining pulsed radiofrequency (PRF) treatment with platelet-rich plasma (PRP) for patients suffering from idiopathic glossopharyngeal neuralgia (GPN). Participants must be over 18 years old and have previously failed pharmacotherapy or experienced intolerable side effects from medications. The study will monitor patients undergoing PRF treatment for GPN, with follow-up assessments conducted for at least one month to evaluate outcomes. The goal is to determine if this combined approach can provide better relief from symptoms compared to standard treatments.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 diagnosed with idiopathic GPN who have not responded to or cannot tolerate conventional medications.
Not a fit: Patients with bilateral GPN or those with significant medical contraindications such as infections or previous mental illness may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could offer a new, effective treatment option for patients suffering from glossopharyngeal neuralgia.
How similar studies have performed: While the combination of PRF and PRP is a novel approach, similar studies have shown promise in treating other neuralgias, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. age \>18 years; 2. diagnosed with idiopathic GPN according to the third International Classification of Headache Disorders (ICHD) classification; 3. patients who failed pharmacotherapy or intolerable side effects of medication; 4. undergoing PRF for GPN; 5. at least 1 month of follow-up recordings. Exclusion Criteria: 1. Patients with bilateral GPN; 2. Abnormalities in blood measurements, liver and kidney function, blood glucose, coagulation, electrocardiography or chest radiography; 3. Infection at the puncture site; 4. Previous mental illness; 5. Previous history of narcotic drug abuse; 6. Prior anticoagulant or antiplatelet therapy; 7. An implantable pulse generator; 8. Current pregnancy or breast feeding. 9. Patients with incomplete medical records (lack of baseline data or postoperative follow-up data).
Where this trial is running
Beijing, Beijing Municipality
- Beijing Tiantan Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Fang Luo, M.D.
- Email: 13611326978@163.com
- Phone: +86 13611326978
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.